Crinetics Pharmaceuticals (CRNX) Competitors $44.15 +0.10 (+0.23%) Closing price 04:00 PM EasternExtended Trading$44.07 -0.08 (-0.18%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, and RVMDShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Crinetics Pharmaceuticals (NASDAQ:CRNX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. Is CRNX or ASND more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -32.28% -29.45% Ascendis Pharma A/S -54.94%N/A -24.31% Do analysts prefer CRNX or ASND? Crinetics Pharmaceuticals currently has a consensus target price of $74.45, indicating a potential upside of 68.64%. Ascendis Pharma A/S has a consensus target price of $248.29, indicating a potential upside of 19.88%. Given Crinetics Pharmaceuticals' higher possible upside, research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the media prefer CRNX or ASND? In the previous week, Ascendis Pharma A/S had 8 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 5 mentions for Crinetics Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.65 beat Crinetics Pharmaceuticals' score of 0.49 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of CRNX or ASND? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, CRNX or ASND? Crinetics Pharmaceuticals has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Which has preferable valuation and earnings, CRNX or ASND? Crinetics Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M3,998.12-$298.41M-$4.11-10.74Ascendis Pharma A/S$393.54M32.47-$409.12M-$5.16-40.14 SummaryAscendis Pharma A/S beats Crinetics Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.16B$2.62B$6.05B$10.51BDividend YieldN/A57.77%5.73%4.80%P/E Ratio-10.7422.7985.3627.35Price / Sales3,998.12557.62516.10196.40Price / CashN/A174.0137.5761.53Price / Book3.095.5112.426.82Net Income-$298.41M$33.06M$3.32B$276.80M7 Day Performance-0.63%0.96%0.97%0.26%1 Month Performance30.74%14.26%10.70%8.29%1 Year Performance-23.35%0.86%76.19%35.59% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.7504 of 5 stars$44.15+0.2%$74.45+68.6%-17.0%$4.16B$1.04M-10.74210ASNDAscendis Pharma A/S3.1962 of 5 stars$210.83+3.3%$244.36+15.9%+62.5%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeVTRSViatris2.4325 of 5 stars$10.13-0.6%$10.40+2.7%-12.8%$11.88B$14.74B-3.4932,000News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories2.7137 of 5 stars$14.12-0.3%$16.95+20.0%-11.6%$11.82B$3.81B21.3927,811News CoveragePositive NewsMRNAModerna4.26 of 5 stars$27.54-3.3%$41.81+51.8%-54.5%$11.08B$3.24B-3.665,800ROIVRoivant Sciences3.063 of 5 stars$16.26+0.6%$19.94+22.6%+38.5%$11.04B$29.05M-23.23860Insider TradeQGENQIAGEN4.3804 of 5 stars$46.99+0.4%$49.40+5.1%+10.8%$10.40B$1.98B27.765,765ELANElanco Animal Health2.78 of 5 stars$20.68+0.2%$18.33-11.3%+41.0%$10.25B$4.44B24.059,000Analyst RevisionBBIOBridgeBio Pharma4.1045 of 5 stars$54.61+3.3%$63.94+17.1%+119.2%$10.11B$221.90M-13.35400VRNAVerona Pharma PLC American Depositary Share1.4594 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.1145 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.73B$11.58M-10.35250 Related Companies and Tools Related Companies Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Roivant Sciences Competitors QIAGEN Competitors Elanco Animal Health Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Revolution Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
